The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications

European Journal of Cancer

Volumn 40, Issue 15, 2004, Pages 2217-2229

  Burger, Angelika M ^a   Seth, Arun K ^a,b  

^a Department of Anatomic Pathology

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; E3 ligases; Proteasome; Ubiquitination; UP S inhibition

Indexed keywords

ALDEHYDE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; EPOXOMICIN; GELDANAMYCIN; ISOENZYME; LACTACYSTIN; LIGASE INHIBITOR; METHIONINE DERIVATIVE; METHIONYL AMINOPEPTIDASE; PEPTIDE DERIVATIVE; PROTEASOME INHIBITOR; PROTEIN MDM2; PROTEIN P53; UBIQUITIN; ZINC DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CATALYSIS; CHIMERA; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EUKARYOTIC CELL; GENE SILENCING; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SOLID TUMOR; UBIQUITINATION;

EID: 5344234076     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.07.006     Document Type: Article

References (93)

1. K.L. Rock, and A.L. Goldberg Degradation of cell proteins and the generation of MHC class1-presented peptides Ann. Rev. Immunol. 17 1999 139 179
2. P. Bohley The fates of proteins in cells Naturwissenschaften 82 1995 544 550
3. M.H. Glickman, and A. Ciechanover The ubiquitinâ€" proteasome proteolytic pathway: destruction for the sake of construction Physiol. Rev. 82 2002 373 428
4. A. Ciechanover, A. Orian, and A.L. Schwartz The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications J. Cell Biochem. Suppl. 34 2000 40 51
5. A.L. Goldberg, R. Stein, and J. Adams New insights into proteasome function: from archaebacteria to drug development Chem. Biol. 2 1995 503 508
6. J. Adams The proteasome: structure, function, and role in the cell Cancer Treatment Rev. 29 2003 3 9
7. A. Hershko, H. Heller, S. Elias, and A. Ciechanover Components of ubiquitinâ€"protein ligase system J. Biol. Chem. 258 1983 8206 8214
8. L. Hicke Protein regulation by monoubiquitination Nat. Rev. Mol. Cell. Biol. 2 2001 195 201
9. Y. Yang, C.C.H. Li, and A.M. Weissman Regulating the p53 system through ubiquitination Oncogene 23 2004 2096 2106
10. M. Li, C.L. Brooks, F. Wu-Baer, D. Chen, R. Baer, and W. Gu Mono- versus polyubiquitination: differential control of p53 fate by Mdm2 Science 302 2003 1972 1975
11. W.L. Gerards, W.W. de Jong, W. Boelens, and H. Bloemendal Structure and assembly of the 20S proteasome Cell. Mol. Life Sci. 54 1998 253 262
12. A.P. Arrigo, K. Tanaka, A.L. Goldberg, and W.J. Welch Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells the proteasome Nature 331 1988 192 194
13. A.J. Rivett The multicatalytic proteinase of mammalian cells Arch. Biochem. Biophys. 268 1989 1 8
14. P.E. Falkenburg, C. Haass, and P.M. Kloetzel Drosophila small cytoplasmic 19S ribonucleoprotein is homologous to the rat multicatalytic proteinase Nature 331 1988 190 192
15. K.M. Sakamoto Ubiquitin-dependent proteolysis: its role in human disease and the design of therapeutic strategies Mol. Genet. Metab. 77 2002 44 56
16. A. Seth, R. Kitching, G. Landberg, J. Zubovitz, J. Xu, and A.M. Burger Identification of genes differentially expressed in ductal carcinoma in situ and invasive breast tumours Anticancer Res. 23 2003 2043 2052
17. D. Dutaud, L. Aubry, and L. Henry Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma J. Immunol. Methods 260 2002 183 193
18. T.R. Pray, F. Parlati, and J. Huang Cell cycle regulatory E3 ubiquitin ligases as anticancer targets Drug Resist. Updates 5 2002 249 258
19. G. Nalepa, and W. Harper Therapeutic anti-cancer targets upstream of the proteasome Cancer Treat. Rev. 29 2003 49 57
20. Y. Okamoto, T. Ozaki, K. Miyazaki, M. Aoyama, M. Miyazaki, and A. Nakagawara UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme Cancer Res. 63 2003 4167 4173
21. M. Fukuchi, Y. Fukai, and N. Masuda High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma Cancer Res. 62 2002 7162 7165
22. L. Monney, I. Otter, and R. Olivier Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2 J. Biol. Chem. 273 1998 6121 6131
23. V. Subramaniam, H. Li, and M. Wong The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of smurf2 E3 ligase Br. J. Cancer 89 2003 1538 1544
24. H. Tauber, T. Koehler, and A. Meye Mdm2 mRNA level is a prognostic factor in soft tissue sarcoma Mol. Med. 6 2000 50 59
25. C.E. Bueso-Ramos, T. Manshouri, and M.A. Haidar Abnormal expression of MDM-2 in breast carcinomas Breast Cancer Res. Treat. 37 1996 179 188
26. K. Onel, and C. Cordon-Cardo MDM2 and prognosis Mol. Cancer Res. 2 2004 1 8
27. D.W. Meek, and U. Knippschild Posttranslational modification of MDM2 Mol. Cancer Res. 1 2003 1017 1026
28. M.K. Connor, and A. Seth A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interaction with E2s and E3s Oncogene 23 2004 2089 2095
29. Y. Zhang, C. Chang, D.J. Gehling, A. Hemmati-Brivanlou, and R. Derynck Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase Proc. Natl. Acad. Sci. USA 98 2001 974 979
30. L. Attisano, and J.L. Wrana Signal transduction by the TGF-beta superfamily Science 296 2002 1646 1647
31. C.A.P. Joazeiro, and A.M. Weissmann RING finger proteins: mediators of ubiquitin ligase activity Cell 102 2000 549 552
32. Y. Dong, M.A. Hakimi, and X. Chen Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair Mol. Cell. 12 2003 1087 1099
33. B.S. Mitchell The proteasome â€" an emerging therapeutic target in cancer N. Engl. J. Med. 348 2003 2597 2598
34. G. Fenteany, R.F. Standaert, W.S. Lane, S. Choi, E.J. Corey, and S.L. Schreiber Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin Science 268 1995 726 731
35. G. Fenteany, and S.L. Schreiber Lactacystin, proteasome function, and cell fate J. Biol. Chem. 273 1998 8545 8548
36. J. Adams Development of the proteasome inhibitor PS-341 The Oncologist 7 2002 9 16
37. L. Meng, R. Mohan, B.H.B. Kwok, M. Elofsson, N. Sin, and C.M. Crews Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity Proc. Natl. Acad. Sci. USA 98 1998 10403 10408
38. D.H. Lee, and A.L. Goldberg Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in saccharomyces cerevisiae J. Biol. Chem. 271 1996 27280 27284
39. J. Adams, V.J. Palombella, and E.A. Sausville Proteasome inhibitors: a novel class of potent and effective antitumour agents Cancer Res. 59 1999 2615 2622
40. E.B. Traenckner, S. Wilk, and P.A. Baeuerle A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B EMBO J. 13 1994 5433 5441
41. B.O. Oyajobi, and G.R. Mundy Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma Cancer 97 2003 813 817
42. No authors listed. Bortezomib (velcade) for multiple myeloma. Med Lett Drugs Ther 2003;45:57-58
43. P.M. Vorhees, E.C. Dees, B. O'Neil, and R.Z. Orlowski The proteasome as a target for cancer therapy Clin. Cancer Res. 15 2003 6316 6325
44. E. Seemueller, A. Lupas, D. Stock, J. Loewe, R. Huber, and W. Baumeister Proteasome from Thermoplasma acidophilum: a threonine protease Science 268 1995 579 582
45. T. Hideshima, D. Chauhan, and P. Richardson NF-κB as therapeutic target in multiple myeloma J. Biol. Chem. 277 2002 16639 16647
46. Y.H. Ling, L. Liebes, and J.D. Jian Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines Clin. Cancer Res. 9 2003 1145 1154
47. C. Aghajanian, S. Soignet, and D.S. Dizon A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumour malignancies Clin. Cancer Res. 8 2002 2505 2511
48. R.Z. Orlowski, T.E. Stinchcombe, and B.S. Mitchell Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J. Clin. Oncol. 20 2002 4420 4427
49. P.G. Richardson, B. Barlogie, and J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 348 2003 2609 2617
50. S. Hatakeyama, and K.I. Nakayama U-box proteins as a new family of ubiquitin ligases Biochem. Biophys. Res. Commun. 302 2003 625 645
51. Y. Yang, and X. Yu Regulation of apoptosis: the ubiquitous way FASEB 17 2003 790 799
52. L. Coscoy, and D. Ganem PHD domains and E3 ubiquitin ligases: viruses make the connection Trends Cell. Biol. 13 2003 7 12
53. Z. Lu, S. Xu, C. Joazeiro, M.H. Cobb, and T. Hunter The PHD domain of MEKK1 acts as an E3 Ubiquitin Ligase and mediates ubiquitination ad degradation of ERK1/2 Mol. Cell. 9 2002 945 956
54. L.T. Vassilev, B.T. Vu, and B. Graves In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
55. Skp2 SCF ubiquitin ligase complex Nature 416 2002 703 708
56. H. Strohmaier, C.H. Spruck, P. Kaiser, K.A. Won, O. Sangfelt, and S.I. Reed Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line Nature 413 2000 316 322
57. J. Slingerland, and M. Pagano Regulation of the cdk inhibitor p27 and its deregulation in cancer J. Cell. Physiol. 183 2000 10 17
58. E.T. Kipreos, and M. Pagano The F-box protein family Genome Biol. 1 2000 3002.1 3002.7
59. K.M. Sakamoto, K.B. Kim, A. Kumagai, F. Mercurio, C.M. Crews, and R.J. Deshaies Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation Proc. Natl. Acad. Sci. 98 2001 8554 8559
60. K.M. Sakamoto, K.B. Kim, and R. Verma Development of protacs to target cancer-promoting proteins for ubiquitinaion and degradation Mol. Cell. Proteom. 2 2003 1350 1358
61. B.E. Turk, E.C. Griffith, S. Wolf, K. Biemann, Y.H. Chang, and J.O. Liu Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells Chem. Biol. 6 1999 823 833
62. S. Hessen, A. Lonchiks, and N. Issaeva Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2 and HPV-E6-induced proteolysis Proc. Natl. Acad. Sci. USA 99 2002 1532 1537
63. H. Wang, X. Zheng, and P. Oliver MDM2 oncogene as a target for cancer therapy: an antisense approach Int. J. Oncol. 15 1999 653 660
64. Z. Lai, T. Yang, and Y.B. Kim Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination actitiy by small molecular weight inhibitors Proc. Natl. Acad. Sci. 99 2002 14734 14739
65. T. Urano, T. Saito, and T. Tsukui Efp targets 14.3.3σ for proteolysis and promotes breast tumour growth Nature 417 2002 871 875
66. K. Horie, T. Urano, K. Ikeda, and S. Inoue Estorgen-responsive RING-finger protein controls breast cancer growth J. Steroid Biochem. Mol. Biol. 85 2003 101 104
67. K. Horie, T. Urano, and S. Inoue Efp as a new molecular target for breast cancer therapy Anticancer Drugs 14 2003 1 2
68. C.A. Joazeiro, S.S. Wing, H. Huang, J.D. Leverson, T. Hunter, and Y.C. Liu The tyrosine kinase negative regulator cCbl as a RING-type E2-dependent ubiquitinâ€"protein ligase Science 286 1999 309 312
69. L. Duan, Y. Miura, M. Dimri, and B. Majumder Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis J. Biol. Chem. 278 2003 28950 28960
70. G. Levkowitz, S. Oved, and L.N. Klapper c-cbl is a suppressor of the neu oncogene J. Biol. Chem. 275 2000 35532 35539
71. S.S. Sridhar, L. Seymour, and F.A. Shepherd Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer Lancet Oncol. 4 2003 397 406
72. L.N. Klapper, H. Waterman, M. Sela, and Y. Yarden tumour-inhibitory antibodies to HER-2_ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2 Cancer Res. 60 2000 3384 3388
73. Y. Yarden Biology of Her2 and its importance in breast cancer Oncology 61 Suppl 2 2001 1 13
74. D.L. Tait, P.S. Obermiller, A.R. Hatmaker, S. Redlin-Frazier, and J.T. Holt Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability Clin. Cancer Res. 5 1999 1708 1714
75. M. Scheffner, J. Huibregste, R.D. Vierstra, and P.M. Howley The HPV-16 E6 and E6-AP complex functions as a ubiquitinâ€"protein ligase in the ubiquitination of p53 Cell 75 1993 495 505
76. W. Beerheide, H.U. Bernard, Y.J. Tan, A. Ganesan, W.G. Rice, and A.E. Ting Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein J. Natl. Cancer Inst. 91 1999 1211 1220
77. J.M. Matthews, and M. Sunde Zinc fingers â€" folds for many occasions IUBMB Life 54 2002 351 355
78. G.M. Leong, N. Subramaniam, and J. Figueroa Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta- dependent transcription J. Biol. Chem. 276 2001 18243 18243
79. X. Lin, M. Liang, and X.H. Feng Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling J. Biol. Chem. 275 2000 36818 36822
80. R. Kitching, M.J. Wong, and D. Koehler The RING-H2 protein RNF11 is differentially expressed in breast tumours and interacts with HECT-type E3 ligases Biochim. Biophys. Acta 1639 2003 104 112
81. H. Li, and A. Seth An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein Oncogene 23 2004 1801 1808
82. V. Garcia, G. Dominguez, and J.M. Garcia Altered expression of the ZBRK1 gene in human breast carcinomas J. Pathol. 202 2004 224 232
83. S. Hatakeyama, M. Yada, M. Matsumoto, N. Ishida, and K.I. Nakayama U-box proteins as a new family of ubiquitinâ€"protein ligases J. Biol. Chem. 276 2000 33111 33120
84. S. Murata, T. Chiba, and K. Tanaka CHIP: a quality-control E3 liagse collaborating with molecular chaperones Int. J. Biochem. Cell. Biol. 35 2003 572 578
85. W. Xu, M. Marcu, X. Yuan, E. Minnaugh, C. Patterson, and L. Neckers Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu Proc. Natl. Acad. Sci. USA 99 2002 12847 12852
86. P. Zhou, N. Fernandes, and I.L. Dodge ErbB2 degradation mediated by the co-chaperone protein CHIP J. Biol. Chem. 278 2003 13829 13837
87. L. Neckers Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends Mol. Med. 8 2002 S55 S61
88. E.A. Sausville, J.E. Tomazeswski, and P. Ivy Clinical Development of 17-allylamino, 17-demethoxygeldanamycint Curr. Cancer Drug Targets 3 2003 377 383
89. G.L. Johnson, and R. Lapadat Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases Science 298 2002 1911 1912
90. K.S. Smalley A pivotal role for ERK in the oncogenic behaviour of malignant melanoma Int. J. Cancer 104 2003 527 532
91. V. Nardi, M. Azam, and G.Q. Daley Mechanisms and implications of imatinib resistance mutations in BCR-ABL Curr. Opin. Hematol. 11 2004 35 43
92. N.J. Donato, J.Y. Wu, and J. Stapley Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia Cancer Res. 64 2004 672 677
93. D. Chauhan, G. Li, and R. Shringarpure Blockage of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells Cancer Res. 63 2003 6174 6177